Advertisement

Topics

Novartis’ breast cancer drug Kisqali succeeds in phase 3 study in premenopausal women

00:54 EST 9 Nov 2017 | Pharmaceutical Business Review

Novartis’ Kisqali (ribociclib) combination therapy has succeeded in a phase 3 study in premenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.

Original Article: Novartis’ breast cancer drug Kisqali succeeds in phase 3 study in premenopausal women

NEXT ARTICLE

More From BioPortfolio on "Novartis’ breast cancer drug Kisqali succeeds in phase 3 study in premenopausal women"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

Endocrine Disorders
Endocrine disorders are grouped into two categories: hormone imbalance - when a gland produces too much or too little of an endocrine hormone development of lesions (such as nodules or tumors) in the endocrine system, which may or may not affect...